

QUICK HEAL TECHNOLOGIES LIMITED

Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014

CIN: L72200MH1995PLC091408

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2022

(₹ in Crores, except earning per share)

Sr. No	Particulars	Quarter ended			Nine months ended		Year ended
		December 31, 2022 (Unaudited)	September 30, 2022 (Unaudited)	December 31, 2021 (Unaudited)	December 31, 2022 (Unaudited)	December 31, 2021 (Unaudited)	March 31, 2022 (Audited)
1	Income						
	Revenue from operations	66.80	100.94	79.62	228.82	238.19	341.90
	Other income	3.47	5.40	3.63	12.07	13.53	19.20
	Total income	70.27	106.34	83.25	240.89	251.72	361.10
2	Expenses						
	Cost of raw materials consumed	0.21	0.42	0.28	0.86	0.64	1.01
	Purchase of software products	1.78	4.06	2.62	6.51	7.73	13.00
	Increase / (decrease) in inventories of security software products	0.52	(0.68)	(0.20)	0.54	(0.63)	(1.85)
	Employee benefits expense	40.38	39.45	33.36	116.95	100.10	139.49
	Depreciation and amortisation expense	4.17	4.14	4.54	12.26	12.80	17.38
	Other expenses	35.28	29.31	23.08	85.90	58.36	83.39
	Total expenses	82.34	76.70	63.68	223.02	179.00	252.42
3	Profit before tax (1-2)	(12.07)	29.64	19.57	17.87	72.72	108.68
4	Tax expense						
	Current tax						
	Pertaining to profit for the current period	(2.16)	7.28	5.18	5.24	17.77	25.88
	Adjustments of tax relating to earlier periods	(0.14)	-	0.65	(0.14)	0.65	0.65
	Deferred tax (benefit) / charge	(0.48)	0.20	(0.55)	(0.28)	(0.80)	(1.04)
	Total tax expense	(2.78)	7.48	5.28	4.82	17.62	25.49
5	Profit for the period (3-4)	(9.29)	22.16	14.29	13.05	55.10	83.19
6	Other comprehensive income, net of tax						
	Other comprehensive income not to be reclassified to profit or loss in subsequent periods:						
	Re-measurement of defined benefit plans	0.18	0.33	0.09	(0.12)	0.23	0.62
	Net (loss) or gain on FVTOCI assets	-	(0.61)	-	(0.61)	-	2.08
	Other comprehensive income to be reclassified to profit or loss in subsequent periods:						
	Exchange differences on translation of foreign operations	0.38	(0.03)	(0.10)	0.17	(0.18)	(0.25)
	Total other comprehensive income	0.56	(0.31)	(0.01)	(0.56)	0.05	2.45
7	Total comprehensive income (after tax) (5+6)	(8.73)	21.85	14.28	12.49	55.15	85.64
8	Paid-up equity share capital (face value of ₹10 each)	53.07	58.07	57.96	53.07	57.96	58.01
9	Other equity	-	-	-	-	-	569.62
10	Earnings per share of ₹10 each: (not annualised for the quarter)						
	a) Basic	(1.70)	3.82	2.47	2.30	9.21	14.01
	b) Diluted	(1.70)	3.81	2.45	2.29	9.15	13.94



QUICK HEAL TECHNOLOGIES LIMITED
Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014
CIN: L72200MH1995PLC091408


NOTES TO THE STATEMENT OF CONSOLIDATED FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2022

Notes to financial results:

- 1 The above financial results for the quarter and nine months ended December 31, 2022 have been subjected to limited review by the statutory auditors of the Holding Company and reviewed by the Audit Committee and approved by the Board of Directors of the Holding Company at the meeting held on January 24, 2023.
- 2 The Holding Company has completed the liquidation process of its subsidiary namely Quick Heal Technologies Japan K.K., on October 14, 2022 as approved by the board of directors at its meeting held on August 07, 2021.
- 3 The Board of Directors of the Holding Company at its meeting held on July 21, 2022 and the shareholders by way of postal ballot on August 26, 2022, approved the buy back of the Holding Company's fully paid equity shares of the face value of ₹10 each from its shareholder/beneficial owners of equity shares of the Holding Company including promoters of the Holding Company as on the record date, on a proportionate basis through the "tender offer" route at a price of ₹300 per share for an aggregate amount not exceeding ₹150. The Holding Company completed the Buy Back Process on October 28, 2022 and has complied with all the requisite formalities with SEBI and ROC.

During the period ended December 31, 2022, as per the requirement of the Companies Act, 2013, an amount of ₹3.31 and ₹176.63 (Including tax on buy back of ₹34.94) has been utilised from securities premium and retained earnings respectively. In accordance with section 69 of the Companies Act, 2013, capital redemption reserve of ₹5.00 (representing the nominal value of the shares bought back) has been created as an apportionment from retained earnings. Consequent to such buy back, the paid-up equity share capital has reduced by ₹5.00. Further, transaction cost of buy back of shares of ₹1.85 has been reduced from retained earnings.
- 4 The Group is engaged in providing security software solutions. The Chief Operating Decision Maker (CODM) reviews the information pertaining to revenue of each of the target customer group (segments) viz. retail, enterprise & government and mobile. However, based on similarity of activities/products, risk and reward structure, organisation structure and internal reporting systems, the Group has structured its operations into one operating segment viz. anti-virus and as such there is no separate reportable operating segment as defined by Ind AS 108 "Operating segments".
- 5 Previous period's figures have been regrouped / reclassified wherever necessary to make them comparable with the current period's classification / disclosure.

Place: Pune
Date: January 24, 2023



For and on behalf of the Board of Directors


Kailash Katkar
Managing Director
& Chief Executive Officer

DIN: 00397191

QUICK HEAL TECHNOLOGIES LIMITEDRegd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014
CIN: L72200MH1995PLC091408**STATEMENT OF STANDALONE FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2022**

(₹ in crores, except per share data)

Sr. No	Particulars	Quarter ended			Nine months ended		Year ended
		December 31, 2022 (Unaudited)	September 30, 2022 (Unaudited)	December 31, 2021 (Unaudited)	December 31, 2022 (Unaudited)	December 31, 2021 (Unaudited)	March 31, 2022 (Audited)
1	Income						
	Revenue from operations	66.80	100.93	79.62	228.82	237.80	341.55
	Other income	3.85	5.38	3.63	12.42	13.51	19.17
	Total income	70.65	106.31	83.25	241.24	251.31	360.72
2	Expenses						
	Cost of raw materials consumed	0.21	0.42	0.28	0.86	0.64	1.00
	Purchase of security software products	1.78	4.06	2.62	6.51	8.05	13.30
	Increase / (decrease) in inventories of security software products	0.52	(0.68)	(0.20)	0.54	(0.67)	(1.89)
	Employee benefits expense	40.38	39.45	33.07	116.94	99.26	138.34
	Depreciation and amortisation expense	4.17	4.14	4.54	12.26	12.80	17.38
	Other expenses	34.63	29.34	23.41	85.19	59.34	84.97
	Total expenses	81.69	76.73	63.72	222.30	179.42	253.10
3	Profit before exceptional items and tax (1-2)	(11.04)	29.58	19.53	18.94	71.89	107.62
4	Exceptional items (refer note 3)	(0.10)	-	-	(0.10)	2.16	4.06
5	Profit before tax (3-4)	(10.94)	29.58	19.53	19.04	69.73	103.56
6	Tax expense						
	Current tax						
	Pertaining to profit for the current period	(2.16)	7.27	5.15	5.21	17.68	25.76
	Adjustments of tax relating to earlier periods (Net)	(0.14)	-	0.65	(0.14)	0.65	0.65
	Deferred tax (benefit/ charge)	(0.48)	0.20	(0.55)	(0.28)	(0.80)	(1.04)
	Total tax expense	(2.78)	7.47	5.25	4.79	17.53	25.37
7	Profit for the period (5-6)	(8.16)	22.11	14.28	14.25	52.20	78.19
8	Other comprehensive income, net of tax						
	Other comprehensive income not to be reclassified to profit or loss in subsequent periods:						
	Re-measurement of defined benefit plans	0.18	0.33	0.09	(0.12)	0.23	0.62
	Net (loss) or gain on FVTOCI assets	-	(0.61)	-	(0.61)	-	2.08
	Total other comprehensive income	0.18	(0.28)	0.09	(0.73)	0.23	2.70
9	Total comprehensive income (after tax) (7+8)	(7.98)	21.83	14.37	13.52	52.43	80.89
10	Paid-up equity share capital (face value of ₹ 10 each)	53.07	58.07	57.96	53.07	57.96	58.01
11	Other equity (as per balance sheet of previous accounting year)	-	-	-	-	-	569.20
12	Earnings per share of ₹ 10 each: (not annualised except for the year ended March)						
	a) Basic	(1.50)	3.81	2.47	2.51	8.72	13.17
	b) Diluted	(1.50)	3.80	2.45	2.50	8.67	13.10



QUICK HEAL TECHNOLOGIES LIMITED
 Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014
 CIN: L72200MH1995PLC091408

NOTES TO THE STATEMENT OF STANDALONE FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2022

Notes to financial results:

1 The above financial results for the quarter and nine months ended December 31, 2022 have been subjected to limited review by the statutory auditors of the Company and reviewed by the Audit Committee and approved by the Board of Directors of the Company at the meeting held on January 24, 2023.

2 **Impairment / Reversal of Impairment of investments**
 Included in exceptional items

Particulars	Standalone					(₹ in crores)
	Quarter ended			Nine months ended		Year ended
	December 31, 2022	September 30, 2022	December 31, 2021	December 31, 2022	December 31, 2021	March 31, 2022
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Impairment / Reversal of Impairment of investments in wholly owned subsidiaries	(0.10)	-	-	(0.10)	2.16	4.06

3 The Company has completed the liquidation process of its subsidiary namely Quick Heal Technologies Japan K.K., on October 14, 2022 as approved by the board of directors at its meeting held on August 07, 2021.


4 The Board of Directors of the Company at its meeting held on July 21, 2022 and the shareholders by way of postal ballot on August 26, 2022, approved the buy back of the Company's fully paid equity shares of the face value of ₹10 each from its shareholder/beneficial owners of equity shares of the Company including promoters of the Company as on the record date, on a proportionate basis through the "tender offer" route at a price of ₹300 per share for an aggregate amount not exceeding ₹150. The Company completed the Buy Back Process on October 28, 2022 and has complied with all the requisite formalities with SEBI and ROC.

During the period ended December 31, 2022, as per the requirement of the Companies Act, 2013, an amount of ₹ 3.31 and ₹176.63 (including tax on buy back of ₹34.94) has been utilised from securities premium and retained earnings respectively. In accordance with section 69 of the Companies Act, 2013, capital redemption reserve of ₹5.00 (representing the nominal value of the shares bought back) has been created as an apportionment from retained earnings. Consequent to such buy back, the paid-up equity share capital has reduced by ₹5.00. Further, transaction cost of buy back of shares of ₹1.85 has been reduced from retained earnings.

5 The Company is engaged in providing security software solutions. The Chief Operating Decision Maker (CODM) reviews the information pertaining to revenue of each of the target customer group (segments) viz. retail, enterprise & government and mobile. However, based on similarity of activities/products, risk and reward structure, organisation structure and internal reporting systems, the Company has structured its operations into one operating segment viz. anti-virus and as such there is no separate reportable operating segment as defined by Ind AS 108 "Operating segments".

6 Previous period's figures have been regrouped / reclassified wherever necessary to make them comparable with the current period's classification / disclosure.

Place: Pune
 Date: January 24, 2023



For and on behalf of the Board of Directors

[Signature]

Kailash Katkar
 Managing Director
 & Chief Executive Officer

DIN: 00397191